We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

AZD6088 Single Ascending Dose Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00931541
Recruitment Status : Completed
First Posted : July 2, 2009
Last Update Posted : September 10, 2009
Information provided by:

June 30, 2009
July 2, 2009
September 10, 2009
June 2009
Not Provided
Safety variables (vital signs, ECG, EEG, safety laboratory values, body temp) [ Time Frame: Sampling occasions during all visits. ]
Same as current
Complete list of historical versions of study NCT00931541 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics [ Time Frame: Intense PK-sampling during 3 pre-defined study days for PK profiling. ]
  • Pharmacodynamics [ Time Frame: Sampling occasions during 3 pre-defined study days. ]
Same as current
Not Provided
Not Provided
AZD6088 Single Ascending Dose Study
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD6088 After Single Ascending Doses in Healthy Male and Non-Fertile Female Volunteers
The aims of the study are to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD6088 following single ascending dose administration in healthy male and non-fertile females.
Not Provided
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Healthy Volunteers
  • Drug: AZD6088
    Oral solution. Each subject will receive a single-dose of AZD6088.
  • Drug: Placebo
    Oral solution. Each subject will receive a single-dose of placebo.
  • Experimental: A
    AZD6088 oral solution
    Intervention: Drug: AZD6088
  • Experimental: B
    Placebo oral solution
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
August 2009
Not Provided

Inclusion Criteria:

  • Caucasian male and non-fertile female healthy volunteers aged ≥18 to ≤55 years with suitable veins for cannulation or repeated venipuncture.
  • Clinically normal physical findings including supine BP, pulse rate, ECG and laboratory assessments in relation to age, as judged by the investigator.
  • Normal and suitable EEG, as judged by a neurologist

Exclusion Criteria:

  • History of any clinically significant disease or disorder which for instance includes CNS disorder or CV disorder.
  • Any clinically significant abnormalities in clinical chemistry, haematology or urinalysis results as judged by the investigator.
  • Any clinically important abnormalities in the ECG.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United Kingdom
EudraCT N0. 2008-007936-17
Not Provided
Not Provided
MSD, AstraZeneca
Not Provided
Study Director: Biljana Lilja AstraZeneca R&D, Södertälje, Sweden
Principal Investigator: Marianne Kasti Quintiles GDRU, London, UK
September 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP